Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer

Published:2017-10 Issue:1 Volume:147 Page:41-46
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Fleming Nicole D.,Coleman Robert L.,Tung Celestine,Westin Shannon N.,Hu Wei,Sun Yunjie,Bhosale Priya,Munsell Mark F.,Sood Anil K.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference27 articles.

1. Cancer Facts & Figures;American Cancer Society,2017

2. A randomized trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer;Du Bois;J. Natl. Cancer Inst.,2003

3. Cancer of the ovary;Cannistra;N. Engl. J. Med.,2004

4. Intraperitoneal cisplatin and paclitaxel in ovarian cancer;Armstrong;N. Engl. J. Med.,2006

5. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomized controlled trial;Katsumata;Lancet,2009

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic effect of dose-dense paclitaxel plus carboplatin with or without bevacizumab for Japanese patients with epithelial ovarian cancer;International Journal of Clinical Oncology;2024-06-12

2. A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer;Journal of Gynecologic Oncology;2024

3. Exploring the mechanism of resistance to vincristine in breast cancer cells using transcriptome sequencing technology;Oncology Letters;2023-10-05

4. Combined treatment of marizomib and cisplatin modulates cervical cancer growth and invasion and enhances antitumor potential in vitro and in vivo;Frontiers in Oncology;2022-08-30

5. Clinical efficacy of highly agglutinative staphylococcin combined with neoadjuvant chemotherapy on patients with intermediate or advanced oral cancer;Pakistan Journal of Medical Sciences;2022-08-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3